- Scinai Immunotherapeutics has completed a corporate reorganization to establish a dedicated CDMO subsidiary, Scinai Biopharma Services Ltd.
- The company aims to scale its CDMO platform and target approximately $5 million in CDMO revenue in 2026.
Scinai Immunotherapeutics has completed a strategic corporate reorganization to establish a dedicated contract development and manufacturing (CDMO) platform alongside a streamlined research and development (R&D) organization.
The restructuring follows the company’s acquisition of Recipharm Israel Ltd. in February 2026, which included a small-molecule development and manufacturing site in Yavne. The acquired entity has been renamed Scinai Biopharma Services Ltd., and now serves as the company’s fully integrated CDMO subsidiary, consolidating all contract manufacturing operations, including facilities, employees, and customer contracts.
The CDMO platform is built on three components: a Jerusalem site providing biologics development and aseptic manufacturing, the Yavne site supporting small-molecule development and API manufacturing, and a commercial collaboration with Recipharm that extends manufacturing capacity through subcontracting and access to its global network.
The reorganization separates CDMO and R&D activities, positioning Scinai Biopharma Services as a customer-focused contract manufacturing business, while Scinai Immunotherapeutics operates as a leaner R&D organization focused on advancing its therapeutic pipeline. The company stated that this structure is intended to improve capital efficiency and operational focus.
“This reorganization represents a deliberate transformation of how we operate and how we create value. The company’s 2026 priorities include expanding its CDMO customer base in the U.S. and Europe and targeting approximately $5 million in CDMO revenues.”
Amir Reichman, Chief Executive Officer of Scinai
